Ocugen Inc

Затворен

1.33 -0.75

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.33

Максимум

1.35

Ключови измерители

By Trading Economics

Приходи

-5.7M

-25M

Продажби

-45K

1.5M

EPS

-0.07

Марж на печалбата

-1,671.841

Служители

116

EBITDA

-3.1M

-20M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+659.26% upside

Дивиденти

By Acuity

Следващи печалби

4.11.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

28M

444M

Предишно отваряне

2.08

Предишно затваряне

1.33

Ocugen Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

16.08.2026 г., 23:51 ч. UTC

Cryptocurrency Declines Reflect Broader Investor Caution Amid Economic Uncertainties and Geopolitical Tensions.

16.08.2026 г., 23:51 ч. UTC

Japan's GDP growth data highlights economic recovery amid global caution, while U.S. retail sales drop raises concerns over interest rate hikes and geopolitical tensions impact financial stability.

16.08.2026 г., 23:51 ч. UTC

Cryptocurrency and major indices decline amid economic uncertainties, with Bridgewater warning of "crunch time" for capital expenditures and consumer sentiment dropping sharply.

16.08.2026 г., 23:51 ч. UTC

Bitcoin and Ethereum decline as major indices show mixed performance amid cautious market sentiment and concerns over capital expenditures.

16.08.2026 г., 23:51 ч. UTC

NAHB Housing Market Index for August 2026 set to release with forecast of 33.0 amid cautious sentiment and declining builder confidence.

16.08.2026 г., 23:51 ч. UTC

Correlated Moves
Macro News

Bitcoin is lower at $63,022 amid broader market pressures from mixed cryptocurrency movements and recent economic data showing declining U.S. retail sales.

16.08.2026 г., 23:41 ч. UTC

Japan's GDP Growth Preliminary Release Expected to Show Modest +0.02% Year-over-Year Increase Amid Mixed Regional Economic Sentiment

16.08.2026 г., 23:41 ч. UTC

Japan's Q2 GDP Growth Rate Expected at 0.5% Amid Cautious Market Sentiment and Rising Oil Prices

16.08.2026 г., 23:41 ч. UTC

China's July Retail Sales YoY data set for August 17, 2026, forecasts a rise to 1.5%, signaling cautious optimism amid mixed economic indicators.

16.08.2026 г., 23:41 ч. UTC

China's Industrial Production YoY data for July 2026 set to release with a forecasted growth rate of 5.0%, amid cautious market sentiment and concerns over declining fixed asset investment.

16.08.2026 г., 23:41 ч. UTC

Canada's Retail Sales Ex Autos Expected to Rise 0.5% in June Amid Mixed Economic Sentiment

16.08.2026 г., 23:41 ч. UTC

China's Fixed Asset Investment Expected to Decline by 6.2% YoY, Raising Concerns Over Economic Growth

16.08.2026 г., 23:31 ч. UTC

U.S. Industrial Production MoM data for July 2026 set to release on August 18, with cautious optimism amid mixed signals and a forecasted increase of 0.3%.

16.08.2026 г., 23:21 ч. UTC

Philadelphia Fed Manufacturing Index Set for Release Amid Cautious Optimism and Mixed Economic Signals on August 20, 2026.

16.08.2026 г., 23:21 ч. UTC

Canada's New Housing Price Index set for release amid cautious optimism and government infrastructure investments aimed at stabilizing home prices.

16.08.2026 г., 23:11 ч. UTC

China's House Price Index YoY release on August 17, 2026, may reveal ongoing pressures in the housing market amid cautious economic indicators and mixed global market performance.

16.08.2026 г., 23:02 ч. UTC

Correlated Moves

USD/SEK is lower during after-market hours, continuing a downward trend since Friday. Broader market dynamics are influencing the currency pair's movement.

16.08.2026 г., 23:01 ч. UTC

CAD/JPY shows a modest increase in after-hours trading, maintaining an upward trajectory since Friday's close amid a generally positive trading context.

16.08.2026 г., 23:01 ч. UTC

Macro News

The US 30Y Treasury Bond Index is trading lower as mixed China economic data raises concerns about global growth prospects. It pulled back from earlier session highs.

16.08.2026 г., 23:01 ч. UTC

The US 10Y Treasury Bond Index is lower today, trading down from Friday's close. The index remains in the middle of its one-month range.

16.08.2026 г., 23:01 ч. UTC

The CAD/CHF currency pair is higher in after-market hours, reflecting notable strength and unusual activity. It is positioned above its 20-day moving average.

16.08.2026 г., 23:01 ч. UTC

GBP/CHF is trading higher during after-market hours, maintaining a steady upward movement since Friday's close. The asset remains near the upper end of its one-month range.

16.08.2026 г., 23:01 ч. UTC

Gold and silver are trading higher during Sunday’s session, gaining ground since Friday's close. Key economic data from China is expected tomorrow.

16.08.2026 г., 23:01 ч. UTC

Correlated Moves

Gold/NZD is trading higher, supported by rising gold prices against the U.S. dollar and maintaining a position above its 20-day moving average.

16.08.2026 г., 23:01 ч. UTC

Correlated Moves

Gold/SGD is higher today, reflecting a modest increase since Friday's close. The asset remains above its 20-day moving average amid rising silver prices.

16.08.2026 г., 23:01 ч. UTC

Correlated Moves

Gold/JPY is trading higher, reflecting a slight increase since Friday's close. The asset remains above its 20-day moving average and near its one-month range high.

16.08.2026 г., 23:01 ч. UTC

Correlated Moves

Gold/HKD is advancing during the session, reflecting a broader trend as silver also gains. The asset remains above its 20-day moving average.

16.08.2026 г., 23:01 ч. UTC

Correlated Moves

Gold/GBP is trading higher, reflecting a modest advance since Friday's close. The asset remains above its 20-day moving average and near recent highs.

16.08.2026 г., 23:01 ч. UTC

Correlated Moves

Silver/JPY is higher today, supported by a rise in gold and anticipation of key economic data from China.

16.08.2026 г., 23:01 ч. UTC

Correlated Moves

Silver/SGD is rising in the current session, supported by a broader trend in precious metals, with gold also gaining.

Сравнение с други в отрасъла

Ценова промяна

Ocugen Inc Прогноза

Ценова цел

By TipRanks

659.26% нагоре

12-месечна прогноза

Среден 10.25 USD  659.26%

Висок 12 USD

Нисък 8 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Ocugen Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

4 ratings

4

Купи

0

Задържане

0

Продай

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
help-icon Live chat